Zachary R.
Smith

On October 8, 2026, Viatris Inc. (“Viatris”), a global healthcare company, and Pacira BioSciences, Inc. (“Pacira”), a leader in innovative non‑opioid pain therapies, announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Cravath is representing Viatris in connection with the transaction.

On October 1, 2026, Corteva, Inc. (“Corteva”) announced it has successfully spun off its advanced seed and genetics business as a new public company, Vylor, Inc., and will move forward as a leading, pure‑play global crop protection company. Cravath is representing Corteva in connection with the transaction.

Cravath represented the underwriters in connection with the $5 billion registered fixed‑to‑floating rate notes offering of JPMorgan Chase & Co., a leading global financial services firm. The transaction closed on October 22, 2025.

Cravath represented the underwriters in connection with the $4 billion registered fixed‑to‑floating rate subordinated notes offering of JPMorgan Chase & Co., a leading global financial services firm. The transaction closed on July 23, 2025.

Cravath represented the underwriters in connection with the $6 billion registered fixed‑to‑floating rate notes offering of JPMorgan Chase & Co., a leading global financial services firm. The transaction closed on April 22, 2025.

On October 6, 2026, Cravath prepared a memo for its clients entitled “SEC Proposes to Rescind Rule 14a‑8’s ‘Federal Regulation’ of Shareholder Proposals, Amend Rule 14a‑4 and Modernize Proxy Solicitations.” The memo discusses the U.S. Securities and Exchange Commission’s proposed changes to the federal proxy rules, including rescinding Rule 14a‑8, which would end federal regulation as to when a shareholder proposal must be included in a company’s proxy statement, and amending Rule 14a‑4 to expand companies’ ability to exercise discretionary voting authority, with respect to proxies that they receive, on proposals that will be presented at a shareholder meeting but are not included in the company’s proxy materials.

On May 19, 2026, Cravath prepared a memo for its clients entitled “SEC Proposes Rule Amendments to Permit Optional Semiannual Reporting.” The memo examines the U.S. Securities and Exchange Commission’s recently proposed rule amendments that would allow SEC registrants required to file three quarterly reports per fiscal year under existing rules to elect to file a single semiannual report instead.

On November 21, 2025, Cravath prepared a memo for its clients entitled “SEC’s Division of Corporation Finance Significantly Reduces Staff’s Role in the Rule 14a‑8 Process for the 2025‑2026 Season.” The memo examines the Division of Corporation Finance’s (“CorpFin”) changes to the Rule 14a‑8 process for the 2025‑2026 proxy season that greatly reduce the staff’s role in the process.